LIPC and hepatocellular carcinoma: Our preliminary studies found that an FXR agonist could inhibit the transcription of hepatic lipase (HL, encoded by LIPC) in a dose‐ and time‐dependent manner in human hepatoma HepG2 cells and inhibit HL activity [12].